[{"id":"4829b067-17e9-4303-a9f1-a51640780137","acronym":"","url":"https://clinicaltrials.gov/study/NCT07211737","created_at":"2025-10-11T01:28:20.312Z","updated_at":"2025-10-11T01:28:20.312Z","phase":"Phase 1","brief_title":"NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma","source_id_and_acronym":"NCT07211737","lead_sponsor":"Baylor College of Medicine","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2043","study_completion_date":" 12/01/2043","last_update_posted":"2025-10-08"},{"id":"a24dd70d-457e-4bf3-b1b4-2106aa67a692","acronym":"","url":"https://clinicaltrials.gov/study/NCT07064018","created_at":"2025-07-19T14:18:32.626Z","updated_at":"2025-07-19T14:18:32.626Z","phase":"Phase 1/2","brief_title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","source_id_and_acronym":"NCT07064018","lead_sponsor":"University of California, Irvine","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2025-07-14"},{"id":"5e1e2228-b845-457c-bca6-09f91e2f7839","acronym":"","url":"https://clinicaltrials.gov/study/NCT07049848","created_at":"2025-07-05T13:58:03.171Z","updated_at":"2025-07-05T13:58:03.171Z","phase":"Phase 2","brief_title":"SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma","source_id_and_acronym":"NCT07049848","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • doxorubicin hydrochloride"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2025-07-03"},{"id":"7152824f-51d6-434a-a17c-b34a21be5fde","acronym":"","url":"https://clinicaltrials.gov/study/NCT07037004","created_at":"2025-06-28T13:42:45.741Z","updated_at":"2025-06-28T13:42:45.741Z","phase":"Phase 2","brief_title":"Adding a Probiotic (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery","source_id_and_acronym":"NCT07037004","lead_sponsor":"City of Hope Medical Center","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 05/04/2026","start_date":" 05/04/2026","primary_txt":" Primary completion: 05/04/2027","primary_completion_date":" 05/04/2027","study_txt":" Completion: 05/04/2027","study_completion_date":" 05/04/2027","last_update_posted":"2025-06-25"},{"id":"5cc7e0ed-f106-4a96-bfa9-c63f255c96f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06850506","created_at":"2025-03-03T10:01:05.906Z","updated_at":"2025-03-03T10:01:05.906Z","phase":"","brief_title":"Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment","source_id_and_acronym":"NCT06850506","lead_sponsor":"Peking University People's Hospital","biomarkers":" CDH6","pipe":"","alterations":" ","tags":["CDH6"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-27"},{"id":"08b2bc8f-c536-4ab4-95bd-8afe3b23bcd7","acronym":"NRG-GY026","url":"https://clinicaltrials.gov/study/NCT05256225","created_at":"2022-02-25T17:52:52.661Z","updated_at":"2025-02-25T12:28:40.900Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer","source_id_and_acronym":"NCT05256225 - NRG-GY026","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 525","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-24"},{"id":"26646272-f3f1-4cb9-84dd-16ded62b0796","acronym":"","url":"https://clinicaltrials.gov/study/NCT01875601","created_at":"2021-01-29T07:04:49.340Z","updated_at":"2025-02-25T12:36:34.409Z","phase":"Phase 1","brief_title":"NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors","source_id_and_acronym":"NCT01875601","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 06/11/2013","start_date":" 06/11/2013","primary_txt":" Primary completion: 09/08/2015","primary_completion_date":" 09/08/2015","study_txt":" Completion: 09/08/2015","study_completion_date":" 09/08/2015","last_update_posted":"2025-02-24"},{"id":"65d9c2cb-0676-43e5-831c-bcc76a373ee1","acronym":"RESOLVE","url":"https://clinicaltrials.gov/study/NCT05154994","created_at":"2021-12-13T14:12:40.514Z","updated_at":"2025-02-25T12:38:04.917Z","phase":"Phase 1","brief_title":"Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma","source_id_and_acronym":"NCT05154994 - RESOLVE","lead_sponsor":"University of Utah","biomarkers":" ARID1A","pipe":"","alterations":" ","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)"],"overall_status":"Suspended","enrollment":" Enrollment 9","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-24"},{"id":"79649cc6-d582-4cf7-94a7-6b84b6103cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04901702","created_at":"2021-05-25T18:52:49.387Z","updated_at":"2025-02-25T12:28:07.986Z","phase":"Phase 1/2","brief_title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","source_id_and_acronym":"NCT04901702","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" EWSR1 • FLI1","pipe":"","alterations":" ","tags":["EWSR1 • FLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"898413db-97d2-4355-9135-1c43e6af96ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT04458922","created_at":"2021-01-18T21:26:29.307Z","updated_at":"2025-02-25T12:37:37.197Z","phase":"Phase 2","brief_title":"Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma","source_id_and_acronym":"NCT04458922","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EWSR1 • ATF1 • CREB1","pipe":"","alterations":" ","tags":["EWSR1 • ATF1 • CREB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 10/05/2020","start_date":" 10/05/2020","primary_txt":" Primary completion: 11/28/2022","primary_completion_date":" 11/28/2022","study_txt":" Completion: 12/13/2025","study_completion_date":" 12/13/2025","last_update_posted":"2025-02-24"},{"id":"b57cb3c0-4fb2-4fdc-add3-151c7aaf3f51","acronym":"SAINT","url":"https://clinicaltrials.gov/study/NCT03138161","created_at":"2024-04-18T20:51:31.500Z","updated_at":"2025-02-25T12:26:41.043Z","phase":"Phase 1/2","brief_title":"SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT03138161 - SAINT","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 07/31/2031","study_completion_date":" 07/31/2031","last_update_posted":"2025-02-24"},{"id":"c5926a3c-11fc-4d8b-a13e-2af41702c630","acronym":"","url":"https://clinicaltrials.gov/study/NCT03866382","created_at":"2021-01-18T19:04:09.999Z","updated_at":"2025-02-25T12:37:16.517Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","source_id_and_acronym":"NCT03866382","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/13/2019","start_date":" 05/13/2019","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-24"},{"id":"c5baf3d3-95f8-46cc-89ee-2ac65d9ade70","acronym":"","url":"https://clinicaltrials.gov/study/NCT06023641","created_at":"2023-09-05T18:12:33.949Z","updated_at":"2025-02-25T12:29:46.532Z","phase":"Phase 1/2","brief_title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","source_id_and_acronym":"NCT06023641","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TP53 • FOXO1 • MYOD1","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • FOXO1 • MYOD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • cyclophosphamide • vincristine • vinorelbine tartrate • dactinomycin • Onivyde (nanoliposomal irinotecan) • Navelbine oral (vinorelbine tartrate oral) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/13/2024","start_date":" 03/13/2024","primary_txt":" Primary completion: 10/01/2034","primary_completion_date":" 10/01/2034","study_txt":" Completion: 10/01/2037","study_completion_date":" 10/01/2037","last_update_posted":"2025-02-24"},{"id":"f4b4cbe0-4811-4846-aa3a-c12b65f5b2a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06052618","created_at":"2023-09-25T14:10:30.120Z","updated_at":"2025-02-25T12:29:50.276Z","phase":"Phase 2","brief_title":"Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)","source_id_and_acronym":"NCT06052618","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vonjo (pacritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 01/01/2033","primary_completion_date":" 01/01/2033","study_txt":" Completion: 01/01/2034","study_completion_date":" 01/01/2034","last_update_posted":"2025-02-24"},{"id":"251108c9-4fb9-4d2a-b2b3-ca1b2c0bb048","acronym":"","url":"https://clinicaltrials.gov/study/NCT01273168","created_at":"2021-01-18T05:09:01.740Z","updated_at":"2025-02-25T13:39:00.081Z","phase":"Phase 1","brief_title":"Endoxifen in Adults With Hormone Receptor Positive Solid Tumors","source_id_and_acronym":"NCT01273168","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Zonalta (Z-endoxifen hydrochloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"593b542b-470d-465e-ae6a-8f9b079a6849","acronym":"ALLIANCE-ABTC-1604","url":"https://clinicaltrials.gov/study/NCT03107780","created_at":"2021-01-18T15:18:36.892Z","updated_at":"2025-02-25T13:48:22.462Z","phase":"Phase 1","brief_title":"Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer","source_id_and_acronym":"NCT03107780 - ALLIANCE-ABTC-1604","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • MGMT","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/09/2018","start_date":" 07/09/2018","primary_txt":" Primary completion: 03/21/2019","primary_completion_date":" 03/21/2019","study_txt":" Completion: 02/07/2026","study_completion_date":" 02/07/2026","last_update_posted":"2025-02-21"},{"id":"a64e7059-51b9-4bf5-a1c3-321665846a5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02211768","created_at":"2021-01-18T10:21:36.289Z","updated_at":"2025-02-25T13:39:14.783Z","phase":"Phase 1","brief_title":"Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1","source_id_and_acronym":"NCT02211768","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 12/08/2014","start_date":" 12/08/2014","primary_txt":" Primary completion: 09/05/2017","primary_completion_date":" 09/05/2017","study_txt":" Completion: 12/30/2019","study_completion_date":" 12/30/2019","last_update_posted":"2025-02-21"},{"id":"a8dbbb89-8bb1-4f12-ad96-eb67e83dce09","acronym":"","url":"https://clinicaltrials.gov/study/NCT00265798","created_at":"2021-01-18T00:54:12.869Z","updated_at":"2025-02-25T13:47:55.628Z","phase":"Phase 2","brief_title":"Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","source_id_and_acronym":"NCT00265798","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • imatinib • sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 09/14/2005","start_date":" 09/14/2005","primary_txt":" Primary completion: 02/11/2010","primary_completion_date":" 02/11/2010","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2025-02-20"},{"id":"bc39ab78-40de-4c87-a343-8cc08b803775","acronym":"PHANTOM","url":"https://clinicaltrials.gov/study/NCT06298916","created_at":"2024-03-07T21:32:59.829Z","updated_at":"2025-02-25T13:56:04.717Z","phase":"Phase 1/2","brief_title":"64Cu-LNTH-1363S in Patients with Sarcoma or Gastrointestinal Tract Cancer","source_id_and_acronym":"NCT06298916 - PHANTOM","lead_sponsor":"Lantheus Medical Imaging","biomarkers":" FAP","pipe":" | ","alterations":" FAP expression","tags":["FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FAP expression"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-20"},{"id":"c3ccbe27-3d9e-4190-a952-e531da2607f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04890093","created_at":"2021-05-18T12:01:54.563Z","updated_at":"2025-02-25T13:49:09.588Z","phase":"Phase 1/2","brief_title":"Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT04890093","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vincristine • locnartecan (PEN-866)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-20"},{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"9a2be334-2a03-47f4-bac6-d53ac52c474b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05286801","created_at":"2022-03-18T11:54:26.510Z","updated_at":"2025-02-25T14:08:43.679Z","phase":"Phase 1/2","brief_title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","source_id_and_acronym":"NCT05286801","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFA • SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["TNFA • SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-19"},{"id":"cce0df20-21d8-4bec-947f-b02d39935805","acronym":"ARST2031","url":"https://clinicaltrials.gov/study/NCT04994132","created_at":"2023-08-27T06:10:56.547Z","updated_at":"2025-02-25T14:08:23.955Z","phase":"Phase 3","brief_title":"A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma","source_id_and_acronym":"NCT04994132 - ARST2031","lead_sponsor":"Children's Oncology Group","biomarkers":" FOXO1","pipe":"","alterations":" ","tags":["FOXO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • vincristine • dactinomycin • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-18"},{"id":"0a44475b-ada6-49fd-a78d-da7cabf4adaa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02879162","created_at":"2021-01-18T14:08:03.022Z","updated_at":"2025-02-25T14:14:51.028Z","phase":"Phase 2","brief_title":"Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT02879162","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 06/20/2021","primary_completion_date":" 06/20/2021","study_txt":" Completion: 01/29/2025","study_completion_date":" 01/29/2025","last_update_posted":"2025-02-17"}]